Regeneron

Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81%
Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81%
Endpoints
Regeneron
monoclonal antibodies
NIH
COVID-19
Flag link:
Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data
Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data
Fierce Pharma
Regeneron
FDA
Eylea
diabetic retinopathy
NIH
Flag link:
Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?
Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?
Motley Fool
Regeneron
vaccines
antibodies
COVID-19
Flag link:
Regeneron used Cuomo connections to get R&D chief Yancopoulos early COVID testing: NYT
Regeneron used Cuomo connections to get R&D chief Yancopoulos early COVID testing: NYT
Fierce Pharma
Regeneron
George Yancopoulos
Andrew Cuomo
COVID-19
Flag link:
Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases
Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases
Reuters
Regeneron
Roche
clincial trials
COVID-19
Flag link:
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Flag link:
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Flag link:
Novartis’s canakinumab cancer test approaches
Novartis’s canakinumab cancer test approaches
EP Vantage
Novartis
Regeneron
canakinumab
cancer
non-small cell lung cancer
Flag link:
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Endpoints
Amgen
patents
Sanofi
Regeneron
Praluent
Repatha
Merck
Flag link:
Regeneron's Evkeeza, carrying big price tag, wins FDA approval in ultra-rare cholesterol disease
Regeneron's Evkeeza, carrying big price tag, wins FDA approval in ultra-rare cholesterol disease
Fierce Pharma
Regeneron
Evkeeza
Homozygous Familial Hypercholesterolemia
FDA
Flag link:
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Yahoo/Benzinga
Sanofi
Regeneron
Libtayo
FDA
advanced basal cell carcinoma
skin cancer
Flag link:
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Endpoints
Dupixent
Regeneron
Sanofi
eczema
Flag link:
Mark Your Calendar For February PDUFA Dates
Mark Your Calendar For February PDUFA Dates
Yahoo/Benzinga
FDA
Adamas Pharmaceuticals
Gocovri
Mallinckrodt
StrataGraft
Regeneron
evinacumab
Sanofi
Sarepta
TG Therapeutics
Flag link:
Regeneron COVID-19 drug cocktail combats South Africa variant, Lilly's does not - study
Regeneron COVID-19 drug cocktail combats South Africa variant, Lilly's does not - study
Reuters
Regeneron
Eli Lilly
antibodies
COVID-19
Flag link:
Go or no go? Oncology decisions ahead for the FDA
Go or no go? Oncology decisions ahead for the FDA
EP Vantage
FDA
cancer
oncology
Bristol-Myers Squibb
TG Therapeutics
Mallinckrodt
Sanofi
Regeneron
Sarepta Therapeutics
GSK
Oncopeptide
Flag link:
Regeneron says monoclonal antibodies prevent Covid-19 in study
Regeneron says monoclonal antibodies prevent Covid-19 in study
Stat
Regeneron
antibodies
COVID-19
Flag link:
Roche eyes FDA filing after bispecific matches Eylea again
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Roche
bispecifics
Regeneron
Eylea
clinical trials
faricimab
wet age-related macular degeneration
Flag link:
US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug
US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug
BioPharma Dive
Regeneron
COVID-19
antibodies
government contracts
Flag link:
JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon
JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon
Fierce Biotech
Regeneron
FDA
odronextamab
clinical hold
B-cell non-Hodgkin lymphoma
Flag link:
Clinical developments over the holidays
Clinical developments over the holidays
EP Vantage
Aprea Therapeutics
Arcturus Therapeutics
Axsome Therapeutics
Inovio
Regeneron
clinical trials
oncology
vaccines
COVID-19
Flag link:

Pages